Physician profile
James R Smith
NPI 1215043062
$1,179.40
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $178 · 2021: $456 · 2022: $134 · 2023: $34.19 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $307.96 | 2019-2021 | |
| Abbott Laboratories | $246.44 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $166.89 | 2019-2021 | |
| Novo Nordisk INC | $136.43 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Merck Sharp & Dohme LLC | $42.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $31.81 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $31.62 | 2022-2023 | Shingrix |
| Amarin Pharma, INC. | $19.13 | 2020 | |
| Antares Pharma, INC. | $17.56 | 2019 | |
| Amgen INC. | $14.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.21 | 2019 | |
| Sanofi Pasteur INC. | $12.75 | 2019 | |
| Eisai INC. | $12.62 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.45 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.